Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageSupernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.
In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR
Business segments
Q1 2026 · $207.7MThe company’s own SEC segment disclosure.
- Qelbree$77.8M37%
- GOCOVRI$35.2M17%
- Royalty License And Other$29.3M14%
- Collaboration$27.6M13%
- Trokendi Xr$9.5M5%
- ONAPGO$8.4M4%
- Other (3)$19.8M10%
Supernus Pharmaceuticals, Inc. (SUPN) reported revenue of $208M in Q1 2026 (quarter ended March 31, 2026), up 39% from the same quarter a year earlier. That came with a gross margin of 89% and net loss of $2.3M. For the full year FY2025, revenue was $719M (+8.6% year on year) and net income −$39M. Its largest product in 2026-Q1 was Qelbree at $78M, 37% of the disclosed total, just ahead of GOCOVRI at 17%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #19 of 28 by Smart Score